Zynerba Pharmaceuticals Inc. (ZYNE) is scheduled to report 3rd quarter earnings on 11/13/2023. Regarding Q3 estimates, Wall Street analysts expect Zynerba Pharmaceuticals Inc. to post earnings of -$0.21 per share.
Zynerba Pharmaceuticals Inc. (ZYNE) is scheduled to report 3rd quarter earnings on 11/13/2023. Regarding Q3 estimates, Wall Street analysts expect Zynerba Pharmaceuticals Inc. to post earnings of -$0.21 per share.
In this edition of “Rising High,” The Fly conducted an exclusive interview with Sundie Seefried, founder and chief executive officer of Safe Harbor Financial (SHFS), a financial services provider to
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for
Harmony Biosciences (HRMY) announced that it has completed its acquisition of Zynerba Pharmaceuticals (ZYNE). As a result of the merger, Zynerba became a wholly owned subsidiary of Harmony. The common
In this week’s “Rising High,” The Fly’s recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a settlement agreement and a facility sale. TILRAY